Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.42 USD
+0.06 (1.79%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $3.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Arbutus Biopharma Corporation [ABUS]
Reports for Purchase
Showing records 41 - 60 ( 191 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
AB-836 Enters HBV Capsid Inhibitor Race With a Robust Phase 1a/1b Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
2020 Financials; AB-729 Powering into Ph 2 Cohorts
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
4Q20 Recap; Expect Data Rich 2021 to Fine-tune AB-729 Dose in New Combination Studies; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
First Triple Combination Study With AB-729 Kicks Off Under Assembly Collaboration
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Expecting New AB-729 Multi Dose Data in 2021; First Phase 2a Combination Trial to Start in 1H21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HBV Pure-Play with Combination Regimen Targeting Functional Cure; Initiate Buy, $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Less Frequent AB-729 Dosing Appears the Way Forward; Reiterate $7 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
AASLD 2020 Takeaways - AB-729 Eying Ph 2; Raising PT to $7
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
AB-729 Dosing Cohorts Continue to Demonstrate Consistent HBsAg Improvement
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
PacGrow Healthcare Conference: Day 1 - 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple AB-729 Cohort Readouts in 2H20
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM and Raising PT to $4; Single- Dose Data Delivers Insight
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R